Summary

Non-muscle Invasive Bladder Cancer Market – Scope of Report
TMR’s report on the global non-muscle invasive bladder cancer market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global non-muscle invasive bladder cancer market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global non-muscle invasive bladder cancer market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the non-muscle invasive bladder cancer market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global non-muscle invasive bladder cancer market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global non-muscle invasive bladder cancer market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global non-muscle invasive bladder cancer market.

The report delves into the competitive landscape of the global non-muscle invasive bladder cancer market. Key players operating in the global non-muscle invasive bladder cancer market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global non-muscle invasive bladder cancer market profiled in this report.

Key Questions Answered in Global non-muscle invasive bladder cancer Market Report
• What is the sales/revenue generated by non-muscle invasive bladder cancer across all regions during the forecast period?
• What are the opportunities in the global non-muscle invasive bladder cancer market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Non-muscle Invasive Bladder Cancer Market – Research Objectives and Research Approach
The comprehensive report on the global non-muscle invasive bladder cancer market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global non-muscle invasive bladder cancer market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global non-muscle invasive bladder cancer market.

ページTOPに戻る

Table of Contents

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Non-muscle Invasive Bladder Cancer Market
4. Market Overview
    4.1. Introduction
        4.1.1. Product Definition
        4.1.2. Industry Evolution/Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Non-muscle Invasive Bladder Cancer Market Analysis and Forecast, 2020-2034
5. Key Insights
    5.1. Pipeline Analysis
    5.2. Key Product /Brand Analysis
    5.3. Key Mergers & Acquisitions
    5.4. COVID-19 Pandemic Impact on Industry
6. Global Non-muscle Invasive Bladder Cancer Market Analysis and Forecast, by Treatment Type
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Treatment Type, 2020-2034
        6.3.1. Immunotherapy
        6.3.2. Chemotherapy
        6.3.3. Targeted Therapy
    6.4. Market Attractiveness Analysis, by Treatment Type
7. Global Non-muscle Invasive Bladder Cancer Market Analysis and Forecast, by Cancer Type
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Cancer Type, 2020-2034
        7.3.1. Low Grade Bladder Cancer
        7.3.2. High Grade Bladder Cancer
    7.4. Market Attractiveness Analysis, by Cancer Type
8. Global Non-muscle Invasive Bladder Cancer Market Analysis and Forecast, by Distribution Channel
    8.1. Introduction & Definition
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by Distribution Channel, 2020-2034
        8.3.1. Hospital Pharmacies
        8.3.2. Retail Pharmacies
        8.3.3. Online Pharmacies
    8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Non-muscle Invasive Bladder Cancer Market Analysis and Forecast, by Region
    9.1. Key Findings
    9.2. Market Value Forecast, by Region, 2020-2034
        9.2.1. North America
        9.2.2. Europe
        9.2.3. Asia Pacific
        9.2.4. Latin America
        9.2.5. Middle East & Africa
    9.3. Market Attractiveness Analysis, by Region
10. North America Non-muscle Invasive Bladder Cancer Market Analysis and Forecast
    10.1. Introduction
    10.2. Key Findings
    10.3. Market Value Forecast, by Treatment Type, 2020-2034
        10.3.1. Immunotherapy
        10.3.2. Chemotherapy
        10.3.3. Targeted Therapy
    10.4. Market Value Forecast, by Cancer Type, 2020-2034
        10.4.1. Low Grade Bladder Cancer
        10.4.2. High Grade Bladder Cancer
    10.5. Market Value Forecast, by Distribution Channel, 2020-2034
        10.5.1. Hospital Pharmacies
        10.5.2. Retail Pharmacies
        10.5.3. Online Pharmacies
    10.6. Market Value Forecast, by Country, 2020-2034
        10.6.1. U.S.
        10.6.2. Canada
    10.7. Market Attractiveness Analysis
        10.7.1. By Treatment Type
        10.7.2. By Cancer Type
        10.7.3. By Distribution Channel
        10.7.4. By Country
11. Europe Non-muscle Invasive Bladder Cancer Market Analysis and Forecast
    11.1. Introduction
    11.2. Key Findings
    11.3. Market Value Forecast, by Treatment Type, 2020-2034
        11.3.1. Immunotherapy
        11.3.2. Chemotherapy
        11.3.3. Targeted Therapy
    11.4. Market Value Forecast, by Cancer Type, 2020-2034
        11.4.1. Low Grade Bladder Cancer
        11.4.2. High Grade Bladder Cancer
    11.5. Market Value Forecast, by Distribution Channel, 2020-2034
        11.5.1. Hospital Pharmacies
        11.5.2. Retail Pharmacies
        11.5.3. Online Pharmacies
    11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
        11.6.1. Germany
        11.6.2. U.K.
        11.6.3. France
        11.6.4. Italy
        11.6.5. Spain
        11.6.6. Rest of Europe
    11.7. Market Attractiveness Analysis
        11.7.1. By Treatment Type
        11.7.2. By Cancer Type
        11.7.3. By Distribution Channel
        11.7.4. By Country/Sub-region
12. Asia Pacific Non-muscle Invasive Bladder Cancer Market Analysis and Forecast
    12.1. Introduction
    12.2. Key Findings
    12.3. Market Value Forecast, by Treatment Type, 2020-2034
        12.3.1. Immunotherapy
        12.3.2. Chemotherapy
        12.3.3. Targeted Therapy
    12.4. Market Value Forecast, by Cancer Type, 2020-2034
        12.4.1. Low Grade Bladder Cancer
        12.4.2. High Grade Bladder Cancer
    12.5. Market Value Forecast, by Distribution Channel, 2020-2034
        12.5.1. Hospital Pharmacies
        12.5.2. Retail Pharmacies
        12.5.3. Online Pharmacies
    12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
        12.6.1. China
        12.6.2. Japan
        12.6.3. India
        12.6.4. Australia & New Zealand
        12.6.5. Rest of Asia Pacific
    12.7. Market Attractiveness Analysis
        12.7.1. By Treatment Type
        12.7.2. By Cancer Type
        12.7.3. By Distribution Channel
        12.7.4. By Country/Sub-region
13. Latin America Non-muscle Invasive Bladder Cancer Market Analysis and Forecast
    13.1. Introduction
    13.2. Key Findings
    13.3. Market Value Forecast, by Treatment Type, 2020-2034
        13.3.1. Immunotherapy
        13.3.2. Chemotherapy
        13.3.3. Targeted Therapy
    13.4. Market Value Forecast, by Cancer Type, 2020-2034
        13.4.1. Low Grade Bladder Cancer
        13.4.2. High Grade Bladder Cancer
    13.5. Market Value Forecast, by Distribution Channel, 2020-2034
        13.5.1. Hospital Pharmacies
        13.5.2. Retail Pharmacies
        13.5.3. Online Pharmacies
    13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
        13.6.1. Brazil
        13.6.2. Mexico
        13.6.3. Rest of Latin America
    13.7. Market Attractiveness Analysis
        13.7.1. By Treatment Type
        13.7.2. By Cancer Type
        13.7.3. By Distribution Channel
        13.7.4. By Country/Sub-region
14. Middle East & Africa Non-muscle Invasive Bladder Cancer Market Analysis and Forecast
    14.1. Introduction
    14.2. Key Findings
    14.3. Market Value Forecast, by Treatment Type, 2020-2034
        14.3.1. Immunotherapy
        14.3.2. Chemotherapy
        14.3.3. Targeted Therapy
    14.4. Market Value Forecast, by Cancer Type, 2020-2034
        14.4.1. Low Grade Bladder Cancer
        14.4.2. High Grade Bladder Cancer
    14.5. Market Value Forecast, by Distribution Channel, 2020-2034
        14.5.1. Hospital Pharmacies
        14.5.2. Retail Pharmacies
        14.5.3. Online Pharmacies
    14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
        14.6.1. GCC Countries
        14.6.2. South Africa
        14.6.3. Rest of Middle East & Africa
    14.7. Market Attractiveness Analysis
        14.7.1. By Treatment Type
        14.7.2. By Cancer Type
        14.7.3. By Distribution Channel
        14.7.4. By Country/Sub-region
15. Competition Landscape
    15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
    15.2. Market Share Analysis, by Company (2023)
    15.3. Company Profiles
        15.3.1. Liminal BioSciences Inc.
            15.3.1.1. Company Overview
            15.3.1.2. Product Portfolio
            15.3.1.3. SWOT Analysis
            15.3.1.4. Financial Overview
            15.3.1.5. Strategic Overview
        15.3.2. TARIS Biomedical LLC
            15.3.2.1. Company Overview
            15.3.2.2. Product Portfolio
            15.3.2.3. SWOT Analysis
            15.3.2.4. Financial Overview
            15.3.2.5. Strategic Overview
        15.3.3. Merck & Co., Inc.
            15.3.3.1. Company Overview
            15.3.3.2. Product Portfolio
            15.3.3.3. SWOT Analysis
            15.3.3.4. Financial Overview
            15.3.3.5. Strategic Overview
        15.3.4. Herantis Pharma Oyj
            15.3.4.1. Company Overview
            15.3.4.2. Product Portfolio
            15.3.4.3. SWOT Analysis
            15.3.4.4. Financial Overview
            15.3.4.5. Strategic Overview
        15.3.5. Viventia Bio Inc.
            15.3.5.1. Company Overview
            15.3.5.2. Product Portfolio
            15.3.5.3. SWOT Analysis
            15.3.5.4. Financial Overview
            15.3.5.5. Strategic Overview
        15.3.6. Telormedix SA
            15.3.6.1. Company Overview
            15.3.6.2. Product Portfolio
            15.3.6.3. SWOT Analysis
            15.3.6.4. Financial Overview
            15.3.6.5. Strategic Overview
        15.3.7. Ferring B.V.
            15.3.7.1. Company Overview
            15.3.7.2. Product Portfolio
            15.3.7.3. SWOT Analysis
            15.3.7.4. Financial Overview
            15.3.7.5. Strategic Overview
        15.3.8. Altor BioScience Corporation
            15.3.8.1. Company Overview
            15.3.8.2. Product Portfolio
            15.3.8.3. SWOT Analysis
            15.3.8.4. Financial Overview
            15.3.8.5. Strategic Overview
        15.3.9. Novartis AG
            15.3.9.1. Company Overview
            15.3.9.2. Product Portfolio
            15.3.9.3. SWOT Analysis
            15.3.9.4. Financial Overview
            15.3.9.5. Strategic Overview
        15.3.10. Pfizer Inc.
            15.3.10.1. Company Overview
            15.3.10.2. Product Portfolio
            15.3.10.3. SWOT Analysis
            15.3.10.4. Financial Overview
            15.3.10.5. Strategic Overview
        15.3.11. GSK plc
            15.3.11.1. Company Overview
            15.3.11.2. Product Portfolio
            15.3.11.3. SWOT Analysis
            15.3.11.4. Financial Overview
            15.3.11.5. Strategic Overview
        15.3.12. Sanofi S.A.
            15.3.12.1. Company Overview
            15.3.12.2. Product Portfolio
            15.3.12.3. SWOT Analysis
            15.3.12.4. Financial Overview
            15.3.12.5. Strategic Overview
        15.3.13. Eli Lilly and Company
            15.3.13.1. Company Overview
            15.3.13.2. Product Portfolio
            15.3.13.3. SWOT Analysis
            15.3.13.4. Financial Overview
            15.3.13.5. Strategic Overview
        15.3.14. AstraZeneca
            15.3.14.1. Company Overview
            15.3.14.2. Product Portfolio
            15.3.14.3. SWOT Analysis
            15.3.14.4. Financial Overview
            15.3.14.5. Strategic Overview